VentriPoint Diagnostics applies for CE Mark for VMS+ device

The machine allows for analysis of all four chambers of the heart
VentriPoint Diagnostics applies for CE Mark for VMS+ device
VentriPoint has developed a suite of applications for all major heart diseases

Medtech group VentriPoint Diagnostics Ltd (CVE:VPT) says it has applied for a CE mark for its ground-breaking VMS+ heart monitoring device.

The machine allows for analysis of all four chambers of the heart using data from a conventional 2D (two dimensional) eco-cardiogram.

"This is a major milestone for the company as it shows the VMS+ device, including the 4-chamber analysis software package, was ready for addition to the company's product registration in Europe," stated Dr George Adams, chief executive of Ventripoint.

The CE mark, allowing goods to be sold in Europe, is recognised worldwide and will allow the company to register these products in many additional countries and regions.

The company will begin this process as soon as the VMS+ has been added to its CE Mark.

The group also said it had been successful in a re-certification audit for its quality management system that is specific to medical devices.

View full VPT profile View Profile

VentriPoint Diagnostics Timeline

Related Articles

numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.